The latest price target for Molecular Partners (NASDAQ:MOLN) was reported by LifeSci Capital on March 11, 2025. The analyst firm set a price target for $12.00 expecting MOLN to rise to within 12 months (a possible 197.03% upside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Molecular Partners (NASDAQ:MOLN) was provided by LifeSci Capital, and Molecular Partners initiated their outperform rating.

The last upgrade for Molecular Partners AG happened on May 25, 2022 when Credit Suisse raised their price target to N/A. Credit Suisse previously had an underperform for Molecular Partners AG.

The last downgrade for Molecular Partners AG happened on August 29, 2022 when SVB Leerink changed their price target from $30 to $8 for Molecular Partners AG.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Molecular Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Molecular Partners was filed on March 11, 2025 so you should expect the next rating to be made available sometime around March 11, 2026.

While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a initiated with a price target of $0.00 to $12.00. The current price Molecular Partners (MOLN) is trading at is $4.04, which is within the analyst’s predicted range.